A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibitor, in patients with mild to moderate atopic dermatitis: a proof-of-concept study with <i>Post-hoc</i> biomarker analysis.

Front Immunol · 2025 · PMC12127193 · PMID 40458407

Europe PMC DOI

hedged sentences

0.0550

closest p · 1.1× alpha

0.0600

boldest claim

The sentences

a negative trendp = 0.055so close (0.05 < p ≤ 0.1)

borderline significancep = 0.055so close (0.05 < p ≤ 0.1)

The “ENTP6 and SMOC1” combination exhibited a negative trend with borderline significance (p = 0.055).

also in 2,510 other papers

borderline significantp = 0.06so close (0.05 < p ≤ 0.1)

Similarly, in the subgroup of patients with moderate atopic dermatitis defined as baseline IGA = 3, the Nu0.5 group showed a borderline significant decrease in IGA score from baseline (-16.7%, 95% CI: -31.3% to -2.0%, p = 0.06) ( Figure 2F ).

also in 6,822 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.